Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $118.1 million as the latest value for Q3 2023.

  • On a quarterly basis, Total Non-Current Liabilities fell 71.61% to $118.1 million in Q3 2023 year-over-year; TTM through Sep 2023 was $118.1 million, a 71.61% decrease, with the full-year FY2022 number at $417.4 million, down 5.45% from a year prior.
  • Total Non-Current Liabilities was $118.1 million for Q3 2023 at Denali Therapeutics, roughly flat from $118.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $453.0 million in Q4 2020 to a low of $118.1 million in Q3 2023.
  • A 5-year average of $296.1 million and a median of $402.6 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 201.41% in 2021, then plummeted 71.61% in 2023.
  • Denali Therapeutics' Total Non-Current Liabilities stood at $158.0 million in 2019, then surged by 186.81% to $453.0 million in 2020, then fell by 2.55% to $441.5 million in 2021, then decreased by 5.45% to $417.4 million in 2022, then crashed by 71.72% to $118.1 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Total Non-Current Liabilities are $118.1 million (Q3 2023), $118.5 million (Q2 2023), and $442.3 million (Q1 2023).